Visionary Holdings (Nasdaq: GV) Establishes Three Wholly Owned Subsidiaries in Qingdao, Wuxi and Wuhu, Advancing Commercial Expansion in China
Rhea-AI Summary
Visionary Holdings (Nasdaq: GV) announced that its subsidiary Visionary Health Technology Group established three wholly owned regional subsidiaries in Qingdao, Wuxi and Wuhu on Feb. 18, 2026 to drive localized commercial expansion for regenerative medicine, cellular rejuvenation and aesthetic treatment products.
The move builds on GV’s Asia headquarters in Hangzhou and sales entity in Nanjing, creating a multi-city commercialization network to support localized sales teams, institutional partnerships, product deployment, and improved revenue visibility.
Positive
- Established three wholly owned subsidiaries in Qingdao, Wuxi and Wuhu (Feb 18, 2026)
- Built multi-city network linking Hangzhou, Nanjing, Qingdao, Wuxi and Wuhu
- Launched stem cell–based anti-aging product portfolio
- Secured global technology licensing in regenerative medicine
- Structured sales pipelines and standardized commercialization processes
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
GV was down 0.87% while momentum peers EEIQ and KIDZ also screened as moving down (median move about -9.0%), pointing to broader pressure in related education names.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 13 | Convertible financing | Negative | +0.9% | Issued $500,000 senior secured convertible note for $450,000 gross proceeds. |
| Feb 04 | Nasdaq deficiency closed | Positive | -2.5% | Nasdaq confirmed continued listing after Form 20-F filing resolved deficiency. |
| Feb 02 | Compliance regained | Positive | +0.0% | Regained compliance with Nasdaq periodic filing rule via FY2025 Form 20-F. |
| Jan 20 | FY2025 results update | Negative | +2.5% | Reported FY2025 revenue $5.04M, 46.2% YoY decline and $15.75M net loss. |
| Jan 13 | FY2025 correction | Negative | +21.9% | Finalized FY2025 report with $5.04M revenue and ~$54.50M negative working capital. |
Recent GV news, whether operational, financing, or compliance-related, often saw share price moves that ran counter to the apparent news tone, with all tracked items showing divergence.
Over the last months, GV reported weak FY2025 fundamentals with revenue of $5.04M, a $15.75M net loss, and about $54.50M in negative working capital, while pivoting toward health, anti-aging, and medical aesthetics. It also resolved Nasdaq filing deficiencies and regained compliance through its January 28, 2026 Form 20-F filing. A $500,000 senior secured convertible note for $450,000 proceeds added financing flexibility but also convertible overhang. Today’s multi-city commercialization update fits that ongoing strategic shift.
Market Pulse Summary
This announcement highlights GV’s shift from platform buildout to active commercialization, adding wholly owned subsidiaries in Qingdao, Wuxi and Wuhu to support regenerative medicine and aesthetic offerings. In context of FY2025 revenue of $5.04M, a $15.75M net loss and significant negative working capital, investors may focus on how this multi-city network converts into measurable sales. Monitoring regional partnership wins, product uptake, and subsequent financing steps will be important for assessing progress.
Key Terms
regenerative medicine medical
nk cell medical
regenerative medicine medical
AI-generated analysis. Not financial advice.
HONG KONG, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Visionary Holdings Inc. (“GV” or the “Company”) (Nasdaq: GV), a technology-driven multinational enterprise, today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited, has established three new regional wholly owned subsidiaries in Qingdao, Wuxi and Wuhu, China.
These subsidiaries are primarily dedicated to localized market expansion, institutional partnerships, and frontline sales execution for GV’s regenerative medicine, cellular rejuvenation, and aesthetic treatment product portfolio.
This development represents a meaningful operational milestone in GV’s transition from strategic platform buildout to coordinated multi-city commercial execution.
Building a Multi-City Commercial Network
Following the launch of GV’s Asia Headquarters in Hangzhou and the establishment of its sales entity in Nanjing, the addition of Qingdao, Wuxi and Wuhu forms a structured regional commercialization matrix covering:
• Shandong Peninsula (Qingdao)
• Yangtze River Delta biomedical corridor (Wuxi)
• Anhui regional healthcare market (Wuhu)
Together, these cities provide diversified healthcare demand bases, strong institutional resources, and access to premium consumer markets.
Core Functions of the Three Subsidiaries
Each regional subsidiary will focus on:
Localized Sales Execution
Recruiting and building professional sales teams to directly support hospitals, aesthetic clinics, and premium wellness institutions.
Institutional Partnerships
Developing strategic cooperation with regional medical providers, healthcare platforms, and channel partners.
Product Deployment and Market Onboarding
Supporting rollout of GV’s stem-cell-based rejuvenation programs, NK cell revitalization therapies, AI-assisted aging assessment systems, and personalized longevity solutions.
Revenue Visibility Enhancement
Establishing structured sales pipelines and standardized commercialization processes to improve revenue visibility and operational transparency.
A Visible Step Forward in Commercialization
Over the past year, GV has executed a phased strategic roadmap:
• Secured global technology licensing in regenerative medicine
• Launched stem cell–based anti-aging product portfolio
• Established Asia-Pacific operational headquarters
• Built frontline sales infrastructure
• Expanded into multiple regional commercialization hubs
The simultaneous establishment of three additional wholly owned subsidiaries reflects continued progress in translating technology assets into structured sales operations.
Management Commentary
Xiyong Hou, Chief Executive Officer of Visionary Holdings, commented:
“The establishment of wholly owned subsidiaries in Qingdao, Wuxi and Wuhu marks an important step in GV’s commercialization journey. We are progressing from strategic positioning to coordinated city-level execution.
By building localized teams and strengthening regional partnerships, we aim to enhance sales capability and operational visibility. Commercialization is a gradual process, but this multi-city deployment strengthens our scalability and long-term growth foundation.
We remain disciplined in execution and focused on delivering measurable progress for our shareholders.”
Strengthening Long-Term Visibility
With operational platforms now spanning Hangzhou, Nanjing, Qingdao, Wuxi and Wuhu, GV has formed an integrated structure covering strategy, technology, product, and regional sales execution.
This expansion enhances:
• Commercial scalability
• Institutional penetration capability
• Revenue pathway visibility
• Regional diversification
As demand for regenerative medicine and aesthetic treatment continues to expand across Asia, GV believes its structured commercialization approach positions the Company to participate meaningfully in this growth trend.
About Visionary Holdings Inc.
Visionary Holdings Inc. (Nasdaq: GV) is a technology-driven multinational enterprise focused on innovative education, AI applications, and high-tech healthcare solutions. Headquartered in Toronto, Canada, the Company operates through its subsidiaries across North America and Asia, driving technological advancement, cross-border innovation, and global health transformation.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "target," "going forward," "outlook," "objective" and similar terms. Such statements are based upon management's current expectations and current market and operating conditions and relate to events that involve known or unknown risks and uncertainties that may cause actual results to differ materially. Further information regarding these and other risks is included in the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov. The Company undertakes no obligation to update any forward-looking statements except as required by law.
Visionary Holdings Inc.
For further information:
Investor Relations
Visionary Holdings Inc.
Email: ir@visionary.holdings
FAQ
What did Visionary Holdings (GV) announce on February 18, 2026 about China expansion?
How do the new GV subsidiaries in Qingdao, Wuxi and Wuhu affect regional coverage in China?
What core functions will GV’s Qingdao, Wuxi and Wuhu subsidiaries perform for GV (Nasdaq: GV)?
Will the new subsidiaries improve revenue visibility for Visionary Holdings (GV)?
Does the Feb 18, 2026 expansion change GV’s Asia organizational structure?
What products will the new GV subsidiaries support in China and when will rollout occur?
